-
Mashup Score: 1
Kate Middleton has revealed that she’s been diagnosed with cancer. The Princess of Wales broke the news in an emotional video, in which she revealed she…
Source: www.facebook.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 0CTG Labs - NCBI - 4 month(s) ago
Hide glossary Study record managers: refer to the Data Element Definitions if submitting registration or results information.
Source: clinicaltrials.govCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 0
MEDIA & INVESTOR RELEASE Novartis Scemblix® shows superior major molecular response (MMR) rates vs. standard-of-care TKIs in Phase III trial for newly diagnosed patients with chronic myeloid leukemia Ad hoc announcement pursuant to Art. 53 MEDIA & INVESTOR RELEASE Novartis is a global healthcare company based in Switzerland that provides solutions to address the evolving needs of patients worldwide.
Source: www.novartis.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 2Cost-Effectiveness Analysis of CAR T-Cell Therapies vs Antibody Drug Conjugates for Patients with Advanced Multiple Myeloma - PubMed - 5 month(s) ago
These findings hinge on the assumption of longer-term survival but suggest that the use of CAR-T therapy is approaching standard ICER thresholds.
Source: pubmed.ncbi.nlm.nih.govCategories: General Medicine News, Hem/OncsTweet-
@amarkelkar @AnnalsofIM @Eddie_Cliff @DrCCutler @ASH_hematology @ASCO @ASTCT @ACPIMPhysicians @CongressmanRaja @Jim_Jordan @SenSanders Excellent work @amarkelkar ! @kandicekapinos and I did work in Myeloma, on cost effectiveness of BCMA targeted therapies. https://t.co/CvgUOzC3rZ So glad to see you were able to see the impact of Rx in various lines. 👏👏
-
-
Mashup Score: 7Limited efficacy of APRIL CAR in patients with multiple myeloma indicate challenges in the use of natural ligands for CAR T-cell therapy - 6 month(s) ago
Background We used a proliferating ligand (APRIL) to construct a ligand-based third generation chimeric antigen receptor (CAR) able to target two myeloma antigens, B-cell maturation antigen (BCMA) and transmembrane activator and CAML interactor. Methods The APRIL CAR was evaluated in a Phase 1 clinical trial ([NCT03287804][1], AUTO2) in patients with relapsed, refractory multiple myeloma. Eleven patients received 13 doses, the first 15×106 CARs, and subsequent patients received 75,225,600 and 900×106 CARs in a 3+3 escalation design. Results The APRIL CAR was well tolerated. Five (45.5%) patients developed Grade 1 cytokine release syndrome and there was no neurotoxicity. However, responses were only observed in 45.5% patients (1×very good partial response, 3×partial response, 1×minimal response). Exploring the mechanistic basis for poor responses, we then compared the APRIL CAR to two other BCMA CARs in a series of in vitro assays, observing reduced interleukin-2 secretion and lack of s
Source: jitc.bmj.comCategories: General Medicine News, Hem/OncsTweet-
@bhemato @GKaurMD @bdermanmd @RahulBanerjeeMD @NatureComms @MJFzeta @MarcelaMaus @DrRakeshPopat had recently published on experience with targeting APRIL with CAR-T. The results make us think 🤔 of ways to over come issues in targeting natural ligands to gain improvement jn efficacy https://t.co/ld9epJ3Zan
-
-
Mashup Score: 1Real-world experience of patients with multiple myeloma receiving ide-cel after a prior BCMA-targeted therapy - 9 month(s) ago
Most patients with multiple myeloma experience disease relapse after treatment with a B-cell maturation antigen-targeted therapy (BCMA-TT), and data describing outcomes for patients treated with sequential BCMA-TT are limited. We analyzed clinical outcomes …
Source: www.ncbi.nlm.nih.govCategories: Hem/Oncs, Latest HeadlinesTweet
-
Mashup Score: 0Post-infusion Costs Associated with Idecabtagene Vicleucel Treatment for Patients with Relapsed/Refractory Multiple Myeloma in the KarMMa Trial - 9 month(s) ago
Advances in Therapy – Patients with triple-class exposed relapsed/refractory multiple myeloma (RRMM) have poor outcomes with substantial healthcare costs. Idecabtagene vicleucel (ide-cel), a B-cell…
Source: link.springer.comCategories: Hem/Oncs, Latest HeadlinesTweet
-
Mashup Score: 1
Fragility scales are intended to help in therapeutic decisions. Here, we asked if the fragility assessment in MM patients ≥ 75 years old qualified for treatment by the local physician correlates with the choice of treatment: a two- or three-drug regimens. Between 7/2018 and 12/2019, we prospectively …
Source: pubmed.ncbi.nlm.nih.govCategories: Hem/Oncs, Latest HeadlinesTweet
-
Mashup Score: 0
Talquetamab is the first therapy targeting GPRC5D to receive a positive CHMP Opinion Teclistamab, the first BCMA-targeting bispecific antibody to…
Source: www.globenewswire.comCategories: Hem/Oncs, Latest HeadlinesTweet
-
Mashup Score: 2Limited efficacy of APRIL CAR in patients with multiple myeloma indicate challenges in the use of natural ligands for CAR T-cell therapy - PubMed - 10 month(s) ago
The APRIL CAR was well tolerated, but the clinical responses observed in AUTO2 were disappointing. Subsequently, when comparing the APRIL CAR to other BCMA CARs, we observed in vitro functional deficiencies due to reduced target binding by cell-expressed ligand.
Source: PubMedCategories: Hem/Oncs, Latest HeadlinesTweet
Wishing Kate Middleton well on her cancer journey. It’s never easy, no matter what we say. I could just imagine what you and your family are going through. Sending positive vibes and thoughts your way 🙏 @UKRoyalNews @KensingtonRoyal https://t.co/p2NM1ZBEwE